Potentially avoidable hospitalizations after chemotherapy: Differences across medicare and the Veterans Health Administration
- 13 May 2020
- Vol. 126 (14), 3297-3302
- https://doi.org/10.1002/cncr.32896
Abstract
Background The Centers for Medicare and Medicaid Services (CMS) has released quality measures regarding potentially avoidable hospitalizations visits in the 30 days after receipt of outpatient chemotherapy. This study evaluated the proportions of patients treated by Medicare‐reimbursed clinicians and Veterans Health Administration (VA) clinicians who experienced avoidable acute care in order to evaluate differences in health system performance. Methods This retrospective evaluation of Medicare and VA administrative data used a cohort of cancer decedents (fiscal years 2010‐2014). Cohort members were veterans aged 66 years or older at death who were dually enrolled in Medicare and the VA. Chemotherapy was identified through International Classification of Diseases, Ninth Revision and Current Procedural Terminology (ICD-9) codes. CMS defines avoidable hospitalizations as those related to anemia, dehydration, diarrhea, emesis, fever, nausea, neutropenia, pain, pneumonia, or sepsis in the 30 days after chemotherapy. Following CMS guidance, this study compared the proportions of patients with potentially avoidable hospitalizations, using hierarchical generalized estimating equations. Results There were 27,443 patients who received outpatient chemotherapy. Patients receiving Medicare chemotherapy were significantly more likely to have potentially avoidable hospitalizations than patients receiving VA chemotherapy (adjusted odds ratio, 1.58; 95% confidence interval, 1.41‐1.78; P < .001). In predicted estimates, 7.1% of Medicare‐treated veterans had potentially avoidable hospitalizations in the 30 days after chemotherapy, compared with 4.6% of VA‐treated veterans. Conclusions Results indicate veterans with cancer receiving chemotherapy in the VA have higher quality care with respect to avoidable hospitalizations than veterans receiving chemotherapy through Medicare. As more veterans seek care in the private sector under the Maintaining Internal Systems and Strengthening Integrated Outside Networks (MISSION) Act, concerted efforts may be warranted to ensure that veterans do not experience a decline in care quality.Keywords
Funding Information
- U.S. Department of Veterans Affairs Health Services Research & Development Service of the VA Office of Research and Development (Merit Review Award Number I01 HX001627)
This publication has 24 references indexed in Scilit:
- Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimensSpringerPlus, 2014
- Predicting chemotherapy toxicity in older adults with lung cancerJournal of Geriatric Oncology, 2013
- Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) scoreCancer, 2011
- Reliance on Veterans Affairs Outpatient Care by Medicare-eligible VeteransMedical Care, 2011
- Chemotherapy-Related Hospitalization Among Community Cancer Center PatientsThe Oncologist, 2011
- Relationship between Clinical Conditions and Use of Veterans Affairs Health Care among Medicare‐Enrolled VeteransHealth Services Research, 2010
- Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United StatesLung Cancer, 2009
- Veterans’ Access to and Use of Medicare and Veterans Affairs Health CareMedical Care, 2007
- Dual-System Use: Are There Implications for Risk Adjustment and Quality Assessment?American Journal of Medical Quality, 2005
- Are Patients at Veterans Affairs Medical Centers Sicker?Archives of Internal Medicine, 2000